Clever Leaves' Q1 Net Loss Drops Significantly After Operating Expenses Slashed By 48%
Clever Leaves' Q1 Net Loss Drops Significantly After Operating Expenses Slashed By 48%
Global medicinal cannabis company Clever Leaves Holdings Inc. (NASDAQ:CLVR) (NASDAQ:CLVRW) reported late Thursday its financial and operating results for the first quarter of 2023.
全球藥用大麻公司 Clever Leaves 控股公司 納斯達克股票代碼：CLVR）（納斯達克股票代碼：CLVRW）週四晚間公佈了其2023年第一季度的財務和經營業績。
CEO Andres Fajardo highlighted the continued commercial momentum in core target markets such as Brazil, Australia and Israel, as well as the ramping up of Colombian smokable dry flower exports.
首席執行官 安德烈斯·法哈多 突顯了巴西、澳大利亞和以色列等核心目標市場的持續商業勢頭，以及哥倫比亞可吸菸乾花出口的增加。
Gross Margin And Net Loss Show Remarkable Improvement
毛利率和淨虧損顯示出顯著改善
By implementing cost reduction measures, Clever Leaves has improved its financial performance in the first quarter of 2023.
通過實施成本削減措施，Clever Leaves改善了其2023年第一季度的財務業績。
Despite a decrease in revenue, the company achieved a higher gross margin and significantly reduced operating expenses, resulting in a substantial decrease in net loss.
儘管收入有所下降，但該公司實現了更高的毛利率並大幅減少了運營支出，從而使淨虧損大幅減少。
Clever Leaves Highlights
聰明的樹葉集錦
- Revenue in the first quarter of 2023 was $4.0 million, compared to $5.0 million in the same period last year.
- Cannabinoid revenue decreased from $1.8 million to $1.2 million, while non-cannabinoid revenue also decreased to $2.8 million.
- Clever Leaves achieved a 480 basis point increase in gross margin, reaching 56.2%.
- The company's cost reduction measures led to a 48% year-over-year decrease in operating expenses and a net loss reduction of nearly 75%.
- Adjusted EBITDA loss improved by 35%, highlighting the benefits of restructuring and cost reduction initiatives.
- Clever Leaves reaffirmed its 2023 outlook, projecting revenue between $19 million and $22 million, with an adjusted gross margin between 58% and 63%.
- The company expects its adjusted EBITDA to range between $(13.6) million and $(10.6) million, representing a significant improvement compared to the previous year.
- Capital expenditures are estimated to decrease by 50% compared to 2022.
- Clever signed partnerships with leading pharmaceutical and cannabis companies, further strengthening its presence in key geographies.
- 2023 年第一季度的收入爲 400 萬美元，而去年同期爲 500 萬美元。
- 大麻素收入從180萬美元下降到120萬美元，而非大麻素收入也降至280萬美元。
- Clever Leaves的毛利率增長了480個基點，達到56.2％。
- 該公司的成本削減措施使運營費用同比下降48％，淨虧損減少了近75％。
- 調整後的息稅折舊攤銷前利潤虧損增加了35％，凸顯了重組和成本削減舉措的好處。
- Clever Leaves重申了其2023年的展望，預計收入在1900萬至2200萬美元之間，調整後的毛利率在58％至63％之間。
- 該公司預計，其調整後的息稅折舊攤銷前利潤將在1,360萬美元至1,060萬美元之間，與去年相比有了顯著改善。
- 與2022年相比，資本支出估計將減少50％。
- Clever 與領先的製藥和大麻公司簽署了合作伙伴關係，進一步加強了其在關鍵地區的影響力。
Read Next: Leafly Achieves Strong Q1 2023 Results: Revenue $11.2M, Net Loss Improves, Retail Accounts Grow By 5.2%
繼續閱讀：Leafly 在 2023 年第一季度取得強勁業績：收入爲 1120 萬美元，淨虧損改善，零售賬戶增長了 5.2%
Photo: Steve Buissinne on Pixabay.
照片：Pixabay 上的 Steve Buissinne。
譯文內容由第三人軟體翻譯。